Resumo

ALFARO CUENCA, Antonia; GALLEGO JORDAN, Berta  e  MARTIN PINERO, Mónica. Study of cost-efficiency for two erythropoietin stimulants in the treatment of anaemia in patients with chronic renal insufficiency under heamodialysis: epoetinum alpha and darbepoetin alpha. Rev Soc Esp Enferm Nefrol [online]. 2004, vol.7, n.3, pp.47-50. ISSN 1139-1375.

The gold standard for the treatment of anaemia in patients with chronic renal insufficiency under haemodialysis is the recombinant human erythropoietin. Recently, a novel treatment for renal anaemia has become available, the darbepoetin alpha, an analogue of human erythropoietin with a longer half-life and more biological activity. The aim of this work is to study the efficiency of darbepoetin alpha, evaluate its cost and compare the relationship cost-efficiency with the standard treatment. We analyzed and compared both treatments (studying dose, haemoglobin, ferritin, number of week administrations, and cost). The conclusion is that darbepoetin alpha is better that epoetinum for the treatment of anaemia in terms of efficiency and cost.

Palavras-chave : Erythropoietin; Cost darbopoetin; Haemodialisis.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )